Ignite Creation Date:
2025-12-25 @ 3:30 AM
Ignite Modification Date:
2026-01-12 @ 6:19 AM
Study NCT ID:
NCT00193505
Status:
COMPLETED
Last Update Posted:
2011-05-03
First Post:
2005-09-12
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma
Sponsor:
SCRI Development Innovations, LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2003-10
Start Date Type:
None
Primary Completion Date:
2005-08
Primary Completion Date Type:
ACTUAL
Completion Date:
2005-08
Completion Date Type:
ACTUAL
First Submit Date:
2005-09-12
First Submit QC Date:
None
Study First Post Date:
2005-09-19
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2011-05-02
Last Update Post Date:
2011-05-03
Last Update Post Date Type:
ESTIMATED